In addition, the HER2-CD3-Fc bsAb activates and recruits T cells to the tumors and harnesses T cells’ potent cytotoxic activity for the targeted killing of the HER2-positive tumor cells, which not only enhances the durability of treatment efficacy, but also reduces the off-target toxicity [71,73]. Here, ERBB2 is linked to neoplasm.